A clinical study of type 2 neurofibromatosis
- PMID: 1484939
A clinical study of type 2 neurofibromatosis
Abstract
The clinical features, age at onset of symptoms and survival of 150 patients with type 2 neurofibromatosis were studied. The mean age at onset was 21.57 years (n = 110) and no patients presented after 55 years of age. Patients presented with symptoms attributable to vestibular schwannomas (acoustic neuroma), cranial meningiomas and spinal tumours. In 100 patients studied personally by the authors 44 per cent presented with deafness and this was unilateral in the majority (35/44). Deafness was accompanied by tinnitus in a further 10 per cent and muscle weakness or wasting was the first symptom in 12 per cent. Less common presenting symptoms were seizures (8 per cent), vertigo (8 per cent) numbness and tingling (2 per cent) and blindness (1 per cent). Eleven patients were diagnosed asymptomatically through screening. Café au lait spots occurred in 43 per cent (n = 43) but only one case had six. Skin tumours were detected in 68 per cent (68/100) and 38 per cent (34/90) had an identifiable lens opacity or cataract. The mean age at death in 40 cases was 36.25 years and all but one death was a result of a complication of neurofibromatosis. There are marked inter-family differences in disease severity and tumour susceptibility.
Similar articles
-
A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.J Med Genet. 1992 Dec;29(12):847-52. doi: 10.1136/jmg.29.12.847. J Med Genet. 1992. PMID: 1479599 Free PMC article.
-
Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.Neuropediatrics. 2005 Feb;36(1):21-34. doi: 10.1055/s-2005-837581. Neuropediatrics. 2005. PMID: 15776319
-
Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females.J Laryngol Otol. 1995 Sep;109(9):830-5. doi: 10.1017/s0022215100131445. J Laryngol Otol. 1995. PMID: 7494114
-
Neurofibromatosis type 2.Handb Clin Neurol. 2015;132:87-96. doi: 10.1016/B978-0-444-62702-5.00005-6. Handb Clin Neurol. 2015. PMID: 26564072 Review.
-
Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.Semin Pediatr Neurol. 2015 Dec;22(4):240-58. doi: 10.1016/j.spen.2015.10.008. Epub 2015 Oct 28. Semin Pediatr Neurol. 2015. PMID: 26706012 Review.
Cited by
-
Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.Anticancer Res. 2013 Jan;33(1):1-11. Anticancer Res. 2013. PMID: 23267122 Free PMC article. Review.
-
Age at Onset and Presenting Symptoms of Neurofibromatosis Type 2 as Prognostic Factors for Clinical Course of Vestibular Schwannomas.Cancers (Basel). 2020 Aug 20;12(9):2355. doi: 10.3390/cancers12092355. Cancers (Basel). 2020. PMID: 32825434 Free PMC article.
-
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.J Clin Oncol. 2019 Dec 10;37(35):3446-3454. doi: 10.1200/JCO.19.01367. Epub 2019 Oct 18. J Clin Oncol. 2019. PMID: 31626572 Free PMC article. Clinical Trial.
-
Neurofibromatosis type 2 (NF2): a clinical and molecular review.Orphanet J Rare Dis. 2009 Jun 19;4:16. doi: 10.1186/1750-1172-4-16. Orphanet J Rare Dis. 2009. PMID: 19545378 Free PMC article. Review.
-
An update on the CNS manifestations of neurofibromatosis type 2.Acta Neuropathol. 2020 Apr;139(4):643-665. doi: 10.1007/s00401-019-02029-5. Epub 2019 Jun 4. Acta Neuropathol. 2020. PMID: 31161239 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Research Materials